Mandate

Vinge advises Mutares in connection with the acquisition of Allianceplus Sweden

Vinge advises the German private equity firm Mutares SE & Co. KGaA in connection with the acquisition of Allianceplus Sweden (“Allianceplus”) from Allianceplus Holding A/S, a portfolio company of Polaris Private Equity.

Allianceplus is engaged in the business of soft facility management. The company is headquartered in Stockholm and offers its services across Sweden with primary focus on Stockholm, Gothenburg, and Malmö. Allianceplus generated approx. EUR 27 million and employed over 500 people in 2020.

Mutares SE & Co. KGaA, a listed private equity holding company with offices in Munich (HQ), Frankfurt, London, Madrid, Milan, Paris, Stockholm and Vienna, acquires small- and medium-sized companies and parts of groups in special situations with headquarters in Europe that show significant potential for operational improvement and are sold again after undergoing a repositioning and stabilization process.

Vinge’s team consisted of Karl Klackenberg and Christina Kokko (M&A), Lisa Hörnqvist (Commercial agreements), Ebba Svenburg (Employment) together with Sebastian Örndahl and Jesper Ekman (Merger filing).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024